Login to Your Account

newco news NEWS
Replicel Life Sciences Inc. is ramping up its pipeline of autologous cell therapies with intentions to file within the next several weeks its plans to initiate early stage trials of its therapies for chronic Achilles tendinosis and aging and sun-damaged skin ahead of pre-trial meetings with Shiseido Co. Ltd., the world's fourth largest cosmetics company and its partner on a developing hair regeneration therapy.

Legochem Biosciences Inc. (LCB) boasts an intuitive name, hearkening to the use of Lego-like scaffolds to enable the discovery of drug candidates. But the platform is more than a toy for scientists.

Shares of Immunovaccine Inc. (TSX:V:IMV) gained 14.4 percent Monday, to close at C$1.11 (US$1.01), after the Halifax, Nova Scotia-based company reported that monkeys dosed with an Ebola vaccine employing its Depovax formulation technology survived exposure to a lethal dose of the virus in a challenge study performed by the National Institute of Allergy and Infectious Diseases (NIAID).
More newco news Headlines

Cast Your Vote

Has biotech’s bubble burst?: